Frank Armstrong

Entelos, Inc. develops predictive computer models of human disease. Its solutions include mechanism-based, mathematical models; virtual patients, populations; biosimulation software and biosimulation expertise. The company was founded in 1996 and is headquartered in San Mateo, CA.

Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK.

BTG Ltd. is a global healthcare company, which focuses on interventional medicine that can help physicians to treat patients through minimally invasive procedures. It operates through the following segments: Product, Licensing, and Other. The firm's products include CroFab, DigiFab, Voraxage. The company was founded on December 12, 1991 and is headquartered in Farnham, the United Kingdom.

Fulcrum Pharma Plc provides drug development and regulatory expertise essential to progress a development program from research to product approval. The company was founded in 1999 and is headquartered in Hemel Hempstead, the United Kingdom.

Avidex Ltd. develops and discovers drugs for the treatment of cancer and autoimmune diseases. The company develops small molecule and protein therapeutics involving T cell receptors. Avidex was founded in 1999 and is headquartered in Abingdon, UK

Gardant Pharmaceuticals, Inc. develops and commercializes pharmaceutical compounds. It develops network for research, clinical development, and project management and guides them through the clinical development and licensing stages. The company was founded in 2000 and is headquartered in New York, NY

454 Life Sciences Corp. engages in the provision of medical testing services to determine the nucleotide sequence of whole genomes. The company was founded by Jonathan M. Rothberg in 2000 and is headquartered in Branford, CT.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Healthcare Royalty Management LLC (Healthcare Royalty) is a private equity subsidiary of Cowen, Inc. founded in 2007 by Gregory Brown. The firm is headquartered in Stamford, Connecticut.

Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis.

Part of Boston Scientific Corp., Provensis Ltd. is a British company that provides health care services. The company is based in Camberley, UK. The company was founded in 1999 by Paul Bernard Harper.

Xceleron Ltd. provides bioanalytical Accelerator Mass Spectrometry (AMS) services for accelerated early drug development. The company uses ultra-sensitive AMS to investigate the pharmacokinetics and metabolism of developmental drugs in Phase 0, Phase I and Phase II/III clinical trials. It was founded in 1997 and is located in York, the United Kingdom.

Zeneca Pharmaceuticals manufactures medicines.

TranScrip Partners LLP is a consultancy provider for biotech and pharmaceutical companies. TranScrip Partners was founded in 2008 and is based in Wokingham, UK. The British company offers development and commercialization services to its clients.

Xceleron, Inc. provides drug development and biomedical research services. Its services include pharmaceutical and analytical method quality. The company was founded by Colin Garner in 1997 and is headquartered in Germantown, MD.

Cardiorentis AG operates as a biopharmaceutical company. It offers novel therapies to the treatment of heart failure and related cardiovascular diseases. The company was founded in 2010 and is headquartered in Zug, Switzerland.

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland.

Part of Rethmann SE & Co. KG, Pharma Action GmbH is a German pharmaceutical company that manufactures pharmaceutical products. The company is based in Berlin, Germany. The CEOs of the company are Erol Isim, Carl E. Bürger. Pharma Action was acquired by Bioibérica SA from Tönnies Lebensmittel GmbH & Co. KG on November 16, 2017.

Caldan Therapeutics Ltd. provides novel therapeutics targeting free fatty acid. It focuses on developing drugs in order to deliver anti-diabetic effects in multiple tissues and organs. The company was founded by Graeme Milligan and Trond Ulven and is headquartered in Edinburgh, the United Kingdom.

AMS Sciences Ltd. provides scientific and technical services. The company was founded on November 2, 2011 and is headquartered in Watfor, the United Kingdom.

Newcells Biotech Ltd. operates as a biotechnology company which produces induced pluripotent stem cells and reproducible cell and tissues. Its cell products include human neural progenitor and cardiomyocyte. The firm also provides reprogramming and differentiation services and products. The company was founded by Majlinda Lako and Lyle Armstrong in 2014 and is headquartered in Newcastle Upon Tyne, the United Kingdom.

BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler.

Enhanc3D Genomics is a private functional genomics company based in Cambridge, UK. Enhanc3D Genomics is developing a technology to unlock the full potential of the three-dimensional organization of the human genome. The British company's focus is on the non-coding regions of the genome, aiming to identify disease-associated genetic interactions and revolutionize target and biomarker discovery. The company's unique approach has the potential to make precision medicine an everyday reality for patients. Enhanc3D Genomics Ltd. was founded by Mikhail Spivakov, Peter Fraser, and Stefan Schönfelder. The CEO is Hazel Jones.

Bloomsbury Genetic Therapies Ltd. is a British biotechnology company that specializes in developing gene therapy technologies for neurological and metabolic diseases. The company is based in Cambridge, UK. Bloomsbury Genetic Therapies was founded in 2021 by Adrien Lemoine, who has been the CEO since 2021.